Hypertension and pregnancy. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology;Hypertension artérielle et grossesse. Consensus d'experts de la Société française d'hypertension artérielle, filiale de la Société française de cardiologie

Presse Medicale

Volumn 45, Issue 7-8, 2016, Pages 682-699

  Mounier Vehier, Claire ^a   Amar, Jacques ^a   Boivin, Jean Marc ^a   Denolle, Thierry ^a   Fauvel, Jean Pierre ^a   Plu Bureau, Geneviève ^b   Tsatsaris, Vassilis ^b   Blacher, Jacques ^a  

^a Soc Francaise d'Hypertension Arter   (France)

^b Collège national des gynécologues et obstétriciens français ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAUSAL ATTRIBUTION; CONSENSUS; DISEASE SEVERITY; FETUS MORTALITY; FRANCE; HEALTH EDUCATION; HUMAN; HYPERTENSION; MATERNAL MORBIDITY; MEDICAL DECISION MAKING; PREGNANCY; RISK ASSESSMENT; TREATMENT PLANNING; CONSENSUS DEVELOPMENT; DECISION TREE; FEMALE; HYPERTENSION, PREGNANCY-INDUCED; PRACTICE GUIDELINE;

DECISION TREES; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PREGNANCY;

EID: 84996917516     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2016.05.012     Document Type: Article

References (131)

1. [1] Thornton, C.E., Dahlen, H.G., Ogle, R., Hennessy, A., Birth outcomes and induction success in hypertensive women: a population based data linkage study (2000–2011). Pregnancy Hypertens, 5, 2015, 73.
2. [2] Kassebaum, N.J., Bertozzi-Villa, A., Coggeshall, M.S., Shackelford, K.A., Steiner, C., Heuton, K.R., et al. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 980–1004.
3. [3] Magee, L.A., Pels, A., Helewa, M., Rey, E., von Dadelszen, P., SOGC Hypertension Guideline Committee, Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive summary. J Obstet Gynaecol Can 36 (2014), 575–576.
4. [4] Ananth, C.V., Peltier, M.R., Kinzler, W.L., Smulian, J.C., Vintzileos, A.M., Chronic hypertension and risk of placental abruption: is the association modified by ischemic placental disease?. Am J Obstet Gynecol, 197, 2007 273.el–7.
5. [5] McCowan, L.M., Buist, R.G., North, R.A., Gamble, G., Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol 103 (1996), 123–129.
6. [6] Khan, K.S., Wojdyla, D., Say, L., Gülmezoglu, A.M., Van Look, P.F., WHO analysis of causes of maternal death: a systematic review. Lancet 367 (2006), 1066–1074.
7. [7] Ronsmans, C., Wendy, J., Graham, on behalf of The Lancet Maternal Survival Series steering group, Maternal mortality: who, when, where, and why?. Lancet 368 (2006), 1189–1200.
8. [8] Gillon, T.E., Pels, A., von Dadelszen, P., MacDonell, K., Magee, L.A., Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One, 9, 2014, e113715.
9. [9] Likert, R.A., A technique for the development of attitude scales. Educ Psychol Meas 12 (1952), 313–315.
10. [10] Sibai, B.M., Chronic hypertension in pregnancy. Obstet Gynecol 100 (2002), 369–377.
11. [11] Rey, E., Couturier, A., The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 171 (1994), 410–416.
12. [12] Regitz-Zagrosek, V., Blomstrom Lundqvist, C., Borghi, C., Cifkova, R., Ferreira, R., Foidart, J.M., et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 32 (2011), 3147–3197.
13. [13] American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy Hypertension in pregnancy, Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122 (2013), 1122–1131.
14. [14] Davison, J.M., Homuth, V., Jeyabalan, A., Conrad, K.P., Karumanchi, S.A., Quaggin, S., et al. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 15 (2004), 2440–2448.
15. [15] Shah, D.M., Preeclampsia: new insights. Curr Opin Nephrol Hypertens 16 (2007), 213–220.
16. [16] Steegers, E.A.P., von Dadelszen, P., Duvekot, J.J., Pijnenborg, R., Pre-eclampsia. Lancet 376 (2010), 631–644.
17. [17] Goffinet, F., Aboulker, D., Paris-Llado, J., Bucourt, M., Uzan, M., Papiernik, E., et al. Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. Br J Obstet Gynaecol 108 (2001), 510–518.
18. [18] Haddad, B., Desvaux, D., Livingston, J.C., Barranger, E., Paniel, B.J., Sibai, B.M., Failure of serum ß2-microglobulin levels as an early marker of preeclampsia. Am J Obstet Gynecol 182 (2000), 595–598.
19. [19] Anumba, D.O.C., Lincoln, K., Robson, S.C., Predictive value of clinical and laboratory indices at first assessment in women referred with suspected gestational hypertension. Hypertens Pregnancy 29 (2010), 163–179.
20. [20] Knight, M., Eclampsia in the United Kingdom 2005. BJOG 114 (2007), 1072–1078.
21. [21] Kullberg, G., Lindeberg, S., Hanson, U., Eclampsia in Sweden. Hypertens Pregnancy 21 (2002), 13–21.
22. [22] Fong, A., Chau, C.T., Pan, D., Ogunyemi, D.A., Clinical morbidities, trends, and demographics of eclampsia: a population based study. Am J Obstet Gynecol, 209, 2013 229.e1–7.
23. [23] Liu, S., Joseph, K.S., Liston, R.M., Bartholomew, S., Walker, M., Leon, J.A., et al. Incidence, risk factors, and associated complications of eclampsia. Obstet Gynecol 118 (2011), 987–994.
24. [24] Thornton, C., Dahlen, H., Korda, A., Hennessy, A., The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000–2008. Am J Obstet Gynecol, 208, 2013 476.e1–5.
25. [25] Zwart, J.J., Richters, A., Ory, F., de Vries, J.I., Bloemenkamp, K.W., van Roosmalen, J., Eclampsia in the Netherlands. Obstet Gynecol 112 (2008), 820–827.
26. [26] Jaatinen, N., Ekholm, E., Eclampsia in Finland; 2006 to 2010. Acta Obstet Gynecol Scand, 2016, 1–8.
27. [27] Sibai, B.M., Eclampsia, V.I., Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 163 (1990), 1049–1054.
28. [28] Douglas, K.A., Redman, C.W.G., Eclampsia in the United Kingdom. BMJ 309 (1994), 1395–1400.
29. [29] Amar, J., Benetos, A., Blacher, J., Bobrie, G., Chamontin, B., Girerd, X., et al. Recommandations de la Societé française d'hypertension artérielle : mesures de la pressure artérielle pour le diagnostic et le suivi du patient hypertendu. Presse Med 41 (2012), 221–224.
30. [30] Macdonald-Wallis, C., Silverwood, R.J., Fraser, A., Nelson, S.M., Tilling, K., Lawlor, D.A., et al. Gestational-age-specific reference ranges for blood pressure in pregnancy: findings from a prospective cohort. J Hypertens 33 (2015), 96–105.
31. [31] Denolle, T., Daniel, J.C., Calvez, C., Ottavioli, J.N., Esnault, V., Herpin, D., Home blood pressure during normal pregnancy. Am J Hypertens 18 (2005), 1178–1180.
32. [32] Contard, S., Chanudet, X., Coisne, D., Battistella, P., Marichal, J.F., Pitiot, M., et al. Ambulatory monitoring of blood pressure in normal pregnancy. Am J Hypertens 6 (1993), 880–884.
33. [33] Churchill, D., Beevers, D.G., Differences between office and 24-hour ambulatory blood pressure measurement during pregnancy. Obstet Gynecol 88 (1996), 455–461.
34. [34] Brown, M.A., Robinson, A., Bowyer, L., Buddle, M.L., Martin, A., Hargood, J.L., et al. Ambulatory blood pressure monitoring in pregnancy: what is normal?. Am J Obstet Gynecol 178 (1998), 836–842.
35. [35] Parati, G., Stergiou, G.S., Asmar, R., Bilo, G., de Leeuw, P., Imai, Y., et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 26 (2008), 1505–1530.
36. [36] Eguchi, K., Ohmaru, T., Ohkuchi, A., Hirashima, C., Takahashi, K., Suzuki, H., et al. Ambulatory BP monitoring and clinic BP in predicting small-for-gestational-age infants during pregnancy. J Hum Hypertens 30 (2016), 62–67.
37. [37] Walker, S.P., Permezel, M.J., Brennecke, S.P., Tuttle, L.K., Higgins, J.R., Patient satisfaction with the SpaceLabs 90207 ambulatory blood pressure monitor in pregnancy. Hypertens Pregnancy 23 (2004), 295–301.
38. [38] Denolle, T., Weber, J.L., Calvez, C., Getin, Y., Daniel, J.C., Lurton, O., et al. Diagnosis of white coat hypertension in pregnant women with teletransmitted home blood pressure. Hypertens Pregnancy 27 (2008), 305–313.
39. [39] von Dadelszen, P., Ornstein, M.P., Bull, S.B., Logan, A.G., Koren, G., Magee, L.A., Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 355 (2000), 87–92.
40. [40] Abalos, E., Duley, L., Steyn, D.W., Antihypertensive drug therapy for mild to moderate hypertension during pregnancy (Review). 2014, The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd, 10.1002/14651858 [Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD002252.pub3.].
41. [41] Magee, L.A., von Dadelszen, P., Rey, E., Ross, S., Asztalos, E., Murphy, K.E., et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 372 (2015), 407–417.
42. [42] Centre de Référence sur les Agents Tératogènes – CRAT. www.lecrat.org.
43. [43] Churchill, D., Beevers, G.D., Meher, S., Rhodes, C., Diuretics for preventing pre-eclampsia. Cochrane Database Syst Rev, 1, 2007, CD004451.
44. [44] Collins, R., Yusuf, S., Peto, R., Overview of randomised trials of diuretics in pregnancy. Br Med J 290 (1985), 17–23.
45. [45] Carr, D.B., Gavrila, D., Brateng, D., Easterling, T.R., Maternal hemodynamic changes associated with furosemide treatment. Hypertens Pregnancy 26 (2007), 173–178.
46. [46] Easterling, T.R., Brateng, D., Schmucker, B., Brown, Z., Millard, S.P., Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 93 (1999), 725–733.
47. [47] Easterling, T.R., Carr, D.B., Brateng, D., Diederichs, C., Schmucker, B., Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 98 (2001), 427–433.
48. [48] Lip, G.Y., Beevers, M., Churchill, D., Shaffer, L.M., Beevers, D.G., Effect of atenolol on birth weight. Am J Cardiol 79 (1997), 1436–1438.
49. [49] Lydakis, C., Lip, G.Y., Beevers, M., Beevers, D.G., Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 12 (1999), 541–547.
50. [50] Center for Disease Control and Prevention, Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy – United States, Canada, and Israel, 1987–1995. JAMA 277 (1997), 1193–1194.
51. [51] Cooper, W.O., Hernandez-Diaz, S., Arbogast, P.G., Dudley, J.A., Dyer, S., Gideon, P.S., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354 (2006), 2443–2451.
52. [52] Pietrement, C., Malot, L., Santerne, B., Roussel, B., Motte, J., Morville, P., Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol 23 (2003), 254–255.
53. [53] Mirshahi, M., Ayani, E., Nicolas, C., Golestaneh, N., Ferrari, P., Valamanesh, F., et al. The blockade of mineralocorticoid hormone signaling provokes dramatic teratogenesis in cultured rat embryos. Int J Toxicol 21 (2002), 191–199.
54. [54] Mounier-Vehier, C., Boudghene, F., Delsart, P., Claisse, G., Kpogbemadou, N., Debarge, V., et al. Cœur, artères et femmes, un circuit de soins dédié aux femmes à risque cardiovasculaire (Trans.) Heart, arteries and women, a care pathway for women at high cardiovascular risk Ann Cardiol Angeiol 63 (2014), 192–196.
55. [55] Winer, N., Branger, B., Collège national des gynécologues et obstétriciens, Société française de médecine périnatale, Société française de néonatalogie, Société française de anesthésie et de réanimation, Management of preeclampsia in a perinatal network. Ann Fr Anesth Reanim 29 (2010), e47–e50.
56. [56] Perez-Cuevas, R., Fraser, W., Reyes, H., Reinharz, D., Daftari, A., Heinz, C.S., et al. Critical pathways for the management of preeclampsia and severe preeclampsia in institutionalised health care settings. BMC Pregnancy Childbirth, 3, 2003, 6.
57. [57] Liu, A., Wen, S.W., Bottomley, J., Walker, M.C., Smith, G., Utilization of health care services of pregnant women complicated by preeclampsia in Ontario. Hypertens Pregnancy 28 (2009), 76–84.
58. [58] Roberts, D., Dalziel, S., Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev, 3, 2006, CD004454.
59. [59] Recommandations formalisées d'experts communes (SFAR/CNGOF/SFMP/SFNN 27 janvier 2009) (Trans.) Multidisciplinary management of severe pre-eclampsia (PE). Experts’ guidelines 2008 Ann Fr Anesth Reanim 28 (2009), 275–281.
60. [60] Duley, L., Henderson-Smart, D., Meher, S., Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst Rev, 4, 2005, CD005548.
61. [61] Ganzevoort, W., Rep, A., Bonsel, G.J., Fetter, W.P., van Sonderen, L., De Vries, J.I., et al. PETRA investigators. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. BJOG 112 (2005), 1358–1368.
62. [62] Crowther, C.A., Hiller, J.E., Doyle, L.W., Haslam, R.R., Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group, Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 290 (2003), 2669–2676.
63. [63] Marret, S., Marpeau, L., Zupan-Simunek, V., Eurin, D., Lévêque, C., Hellot, M.F., et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 114 (2007), 310–318.
64. [64] Rouse, D.J., Hirtz, D.G., Thom, E., Varner, M.W., Spong, C.Y., Mercer, B.M., et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 359 (2008), 895–905.
65. [65] Doyle, L.W., Crowther, C.A., Middleton, P., Marret, S., Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Gynecol 113 (2009), 1327–1333.
66. [66] Duley, L., Gümezoglu, A.M., Henderson-Smart, D.J., Chou, D., Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev, 11, 2010, CD000025.
67. [67] Altman, D., Carroli, G., Duley, L., Farrell, B., Moodley, J., Neilson, J., et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359 (2002), 1877–1890.
68. [68] Belghiti, J., Kayem, G., Tsatsaris, V., Goffinet, F., Sibai, B.M., Haddad, B., Benefits and risks of expectant management of severe preeclampsia at less than 26 weeks gestation: the impact of gestational age and severe fetal growth restriction. Am J Obstet Gynecol, 205, 2011 465.e1–6.
69. [69] Sibai, B.M., Mercer, B.M., Schiff, E., Friedman, S.A., Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks’ gestation: a randomized controlled trial. Am J Obstet Gynecol 171 (1994), 818–822.
70. [70] Odendaal, H.J., Pattinson, R.C., Bam, R., Grove, D., Kotze, T.J., Aggressive or expectant management for patients with severe preeclampsia between 28–34 weeks’ gestation: a randomized controlled trial. Obstet Gynecol 76 (1990), 1070–1075.
71. [71] Ancel, P.Y., Goffinet, F., EPIPAGE-2 Writing Group, Kuhn, P., Langer, B., Matis, J., et al. Survival and morbidity of preterm children born at 22 through 34 weeks’ gestation in France in 2011: results of the EPIPAGE-2 cohort study. JAMA Pediatr 169 (2015), 230–238.
72. [72] Beaufils, M., Uzan, S., Donsimoni, R., Colau, J.C., Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1 (1985), 840–842.
73. [73] Askie, L.M., Duley, L., Henderson-Smart, D.J., Stewart, L.A., PARIS Collaborative Group, Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369 (2007), 1791–1798.
74. [74] Ayala, D.E., Ucieda, R., Hermida, R.C., Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 30 (2013), 260–279.
75. [75] Subtil, D., Goeusse, P., Puech, F., Lequien, P., Biausque, S., Breart, G., et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). BJOG 110 (2003), 475–484.
76. [76] Goffinet, F., Aboulker, D., Paris-Llado, J., Bucourt, M., Uzan, M., Papiernik, E., et al. Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. BJOG 108 (2001), 510–518.
77. [77] Mol, B.W., Roberts, C.T., Thangaratinam, S., Magee, L.A., de Groot, C.J., Hofmeyr, G.J., Pre-eclampsia. Lancet 387 (2016), 999–1011.
78. [78] Meher, S., Duley, L., Exercise or other physical activity for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev, 2, 2006, CD005942.
79. [79] Hackett, G.A., Cohen-Overbeek, T., Campbell, S., The effect of exercise on uteroplacental Doppler waveforms in normal and complicated pregnancies. Obstet Gynecol 796 (1992), 919–923.
80. [80] Sénat, M.V., Sentilhes, L., Battut, A., Benhamou, D., Bydlowski, S., Chantry, A., et al. Post-partum: guidelines for clinical practice – Short text. J Gynecol Obstet Biol Reprod 44 (2015), 1157–1166.
81. [81] Raccah-Tebeka, B., Plu-Bureau, G., Post-partum contraception: guidelines for clinical practice. J Gynecol Obstet Biol Reprod 44 (2015), 1127–1134.
82. [82] Heit, J.A., Kobbervig, C.E., James, A.H., Petterson, T.M., Bailey, K.R., Melton, L.J. 3rd., Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143 (2005), 697–706.
83. [83] Jackson, E., Curtis, K.M., Gaffield, M.E., Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 117 (2011), 691–703.
84. [84] Kamel, H., Navi, B.B., Sriram, N., Hovsepian, D.A., Devereux, R.B., Elkind, M.S., Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 370 (2014), 1307–1315.
85. [85] Raps, M., Helmerhorst, F.M., Fleischer, K., Dahm, A.E., Rosendaal, F.R., Rosing, J., et al. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Thromb Haemost 109 (2013), 606–613.
86. [86] Plu-Bureau, G., Maitrot-Mantelet, L., Hugon-Rodin, J., Canonico, M., Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab 27 (2013), 25–34.
87. [87] Stegeman, B.H., de Bastos, M., Rosendaal, F.R., van Hylckama Vlieg, A., Helmerhorst, F.M., Stijnen, T., et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ, 347, 2013, f5298.
88. [88] Lidegaard, O., Hougaard-Nielsen, L., Wessel-Skovlund, C., Lokkegaard, H., Venous thrombosis in users of non-oral hormonal contraception: follow-up, Denmark 2001–10. BMJ, 344, 2012, e2990.
89. [89] Salonen Ros, H., Lichtenstein, P., Bellocco, Petersson, G., Cnattingius, S., Increased risks of circulatory diseases in late pregnancy and puerperium. Epidemiology 12 (2001), 456–460.
90. [90] Wang, I.K., Chang, S.N., Liao, C.C., Liang, C.C., Chang, C.T., Lin, H.H., et al. Hypertensive disorders in pregnancy and preterm delivery and subsequent stroke in Asian women: a retrospective cohort study. Stroke 42 (2011), 716–721.
91. [91] Plu-Bureau, G., Hugon-Rodin, J., Maitrot-Mantelet, L., Canonico, M., Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab 27 (2013), 35–45.
92. [92] WHO. Medical eligibility criteria for contraceptive use 2015. 5th edition, Geneva: World Health Organization.
93. [93] Plan Cancer : recommandations nationales pour la mise en œuvre du dipositif d'annonce du cancer dans les établissements de santé. http://www.e-cancer.fr/Professionnels-de-sante/Parcours-de-soins-des-patients/Dispositif-d-annonce/Un-temps-fort-du-parcours-de-soins.
94. [94] Cirillo, P.M., Cohn, B.A., Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. Circulation 132 (2015), 1234–1242.
95. [95] Lisonkova, S., Sabr, Y., Mayer, C., Young, C., Skoll, A., Joseph, K.S., Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol 124 (2014), 771–781.
96. [96] Bellamy, L., Casas, J.P., Hingorani, A.D., Williams, D.J., Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ, 335, 2007, 974.
97. [97] Bramham, K., Parnell, B., Nelson-Piercy, C., Seed, P.T., Poston, L., Chappell, L.C., Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ, 348, 2014, g2301.
98. [98] Bushnell, C., McCullough, L.D., Awad, I.A., Chireau, M.V., Fedder, W.N., Furie, K.L., et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45 (2014), 1545–1588.
99. [99] Collins, P., Rosano, G., Casey, C., Daly, C., Gambacciani, M., Hadji, P., et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 28 (2007), 2028–2040.
100. [100] Maas, A.H., van der Schouw, Y.T., Regitz-Zagrosek, V., Swahn, E., Appelman, Y.E., Pasterkamp, G., et al. Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women. Eur Heart J 32 (2011), 1362–1368.
101. [101] Mosca, L., Benjamin, E.J., Berra, K., Bezanson, J.L., Dolor, R.J., Lloyd-Jones, D.M., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the american heart association. Circulation 123 (2011), 1243–1262.
102. [102] Brown, M.C., Best, K.E., Pearce, M.S., Waugh, J., Robson, S.C., Bell, R., Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 28 (2013), 1–19.
103. [103] Harskamp, R.E., Zeeman, G.G., Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 334 (2007), 291–295.
104. [104] Newstead, J., von Dadelszen, P., Magee, L.A., Preeclampsia and future cardiovascular risk. Expert Rev Cardiovasc Ther 5 (2007), 283–294.
105. [105] Hypertension in pregnancy. The management of hypertensive disorders during pregnancy. NICE Clinical Guidelines. No. 107. National Collaborating Centre for Women's and Children's Health (UK). 2010, RCOG Press, London.
106. [106] Adams, T., Yeh, C., Bennett-Kunzier, N., Kinzler, W.L., Long-term maternal morbidity and mortality associated with ischemic placental disease. Semin Perinatol 38 (2014), 146–150.
107. [107] Manten, G.T., Sikkema, M.J., Voorbij, H.A., Visser, G.H., Bruinse, H.W., Franx, A., Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction. Hypertens Pregnancy 26 (2007), 39–50.
108. [108] Karumanchi, S.A., August, P., Podymow, T., Renal complications in normal pregnancy. Floege, J., Johnson, R.J., Feehally, J., (eds.) Comprehensive clinical nephrology, 2011, Mosby, Toronto.
109. [109] Blacher, J., Halimi, J.M., Hanon, O., Mourad, J.J., Pathak, A., Schnebert, B., et al. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol 28 (2014), 1–9.
110. [110] Wilson, B.J., Watson, M.S., Prescott, G.J., Sunderland, S., Campbell, D.M., Hannaford, P., et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ, 326, 2003, 845.
111. [111] James, A.H., Bushnell, C.D., Jamison, M.G., Myers, E.R., Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 106 (2005), 509–516.
112. [112] Ray, J.G., Vermeulen, M.J., Schull, M.J., Redelmeier, D.A., Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 366 (2005), 1797–1803.
113. [113] Smith, G.N., Pudwell, J., Walker, M., Wen, S.W., Ten-year, thirty-year, and lifetime cardiovascular disease risk estimates following a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can 34 (2012), 830–835.
114. [114] Schausberger, C.E., Jacobs, V.R., Bogner, G., Wolfrum-Ristau, P., Fischer, T., Hypertensive disorders of pregnancy – a life-long risk?. Geburtshilfe Frauenheilkd 73 (2013), 47–52.
115. [115] Vikse, B.E., Irgens, L.M., Leivestad, T., Skjaerven, R., Iversen, B.M., Preeclampsia and the risk of end-stage renal disease. N Engl J Med 359 (2008), 800–809.
116. [116] Williams, D., Long-term complications of preeclampsia. Semin Nephrol 31 (2011), 111–122.
117. [117] Kattah, A.G., Asad, R., Scantlebury, D.C., Bailey, K.R., Wiste, H.J., Hunt, S.C., et al. Hypertension in pregnancy is a risk factor for microalbuminuria later in life. J Clin Hypertens (Greenwich) 15 (2013), 617–623.
118. [118] Spaan, J., Lopez van Balen, V.L., Peeters, L., Spaanderman, M., Prevalence of chronic kidney disease after preeclampsia using KDIGO 2012 criteria. Pregnancy Hypertens 5 (2015), 35–36.
119. [119] Berks, D., Hoedjes, M., Raat, H., Duvekot, J.J., Steegers, E.A., Habbema, J.D., Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG 120 (2013), 924–931.
120. [120] Brown, M.A., Mackenzie, C., Dunsmuir, W., Roberts, L., Ikin, K., Matthews, J., et al. Can we predict recurrence of pre-eclampsia or gestational hypertension?. BJOG 114 (2007), 984–993.
121. [121] McDonald, S.D., Best, C., Lam, K., The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population based cohort. BJOG 116 (2009), 1578–1584.
122. [122] van Oostwaard, M.F., Langenveld, J., Schuit, E., Papatsonis, D.N., Brown, M.A., Byaruhanga, R.N., et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol, 212, 2015 624.e1–17.
123. [123] Caritis, S., Sibai, B., Hauth, J., Lindheimer, M.D., Klebanoff, M., Thom, E., et al. Low-dose aspirin to prevent preeclampsia in women at high risk: National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 338 (1998), 701–705.
124. [124] Mito, A., Arata, N., Qiu, D., Sakamoto, N., Ohya, Y., Murashima, A., et al. Blood pressure one month after delivery will predict subsequent hypertension five years after delivery. Pregnancy Hypertens, 5, 2015, 57.
125. [125] Beckmann, M.M., Widmer, T., Bolton, E., Does preconception care work?. Aust N Z J Obstet Gynaecol 54 (2014), 510–514.
126. [126] Robbins, C.L., Zapata, L.B., Farr, S.L., Kroelinger, C.D., Morrow, B., Ahluwalia, I., et al. Core state preconception health indicators – pregnancy risk assessment monitoring system and behavioral risk factor surveillance system, 2009. MMWR Surveill Summ 63 (2014), 1–62.
127. [127] Lowe, S.A., Bowyer, L., Lust, K., McMahon, L.P., Morton, M., North, R.A., et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol 55 (2015), e1–e29.
128. [128] HAS, Recommandations professionnelles. Comment mieux informer les femmes enceintes. 2005 www.has-sante.fr.
129. [129] Rodger, M.A., Walker, M.C., Smith, G.N., Wells, P.S., Ramsay, T., Langlois, N.J., et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost 12 (2014), 469–478.
130. [130] Bates, S.M., Preventing thrombophilia-related complications of pregnancy: an update. Expert Rev Hematol 6 (2013), 287–300.
131. [131] Bates, S.M., Greer, I.A., Middeldorp, S., Veenstra, D.L., Prabulos, A.M., Vandvik, P.O., et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e691S–736S.